Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with sta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:OncoTargets and therapy 2023-01, Vol.16, p.133-139
Hauptverfasser: Alanzi, Meshaal, Abu-Tineh, Mohammad, Szabados, Lajos, Sharaf Eldean, M Z, Alatasi, Sali, Taha, Ruba Y, Elkourashy, Sarah A
Format: Artikel
Sprache:eng
Schlagworte:
Bendamustine
Biopsy
Bone marrow
Burkitt's lymphoma
Cable television broadcasting industry
Cancer
Care and treatment
Case Report
Case reports
Chemotherapy
Drug therapy, Combination
Hybridization
Lymphatic system
Lymphoma
Medical imaging
Medical prognosis
Metabolism
Monoclonal antibodies
Prognosis
Remission
Stem cells
Targeted cancer therapy
Vincristine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S394193